The kinase inhibitor dabrafenib halts progression of cerebral cavernous malformations in a BRAF-independent manner
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
In conclusion, dabrafenib is a low–molecular weight compound that inhibits cavernoma pathogenesis, suggesting that CCMs could be treated with dabrafenib to block cavernoma growth and vascular leakage.
Appeared: Friday, October 23. Science Translational Medicine. Peer-reviewed journal.